Form 4: Maze Therapeutics CEO Sells Shares Under 10b5-1 Plan

Maze Therapeutics, Inc. (MAZE) CEO Jason V. Coloma has reported the sale of company stock through a pre-arranged trading plan.

Summary

• Jason V. Coloma, Chief Executive Officer and Director of Maze Therapeutics, Inc. (MAZE), reported transactions on June 1, 2026.
• These transactions involved the sale of common stock under a Rule 10b5-1 trading plan adopted on February 6, 2026.
• A total of 6,090 shares were sold at a weighted average price of $26.1965, with individual sales ranging from $26.00 to $26.545.
• An additional 553 shares were sold at a weighted average price of $26.2412, with individual sales ranging from $26.00 to $26.50.
• Following these sales, Mr. Coloma's beneficial ownership includes shares held directly and indirectly through trusts.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the CEO's sale of stock, even though it was conducted under a pre-established trading plan.

Negatives

• The CEO sold a significant number of shares (6,643 total) which could be perceived negatively by the market, although executed under a pre-planned trading strategy.

Risks

• The sale of shares by a key executive could be interpreted as a lack of confidence in the company's near-term prospects, despite being executed under a Rule 10b5-1 plan.
• The Rule 10b5-1 plan itself is subject to market conditions and the executive's personal financial planning, which may not align with optimal company performance timing.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes, upon request.

Industry Context

StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are closely watched by investors. While these plans are designed to avoid insider trading concerns, they can still influence market perception, especially for smaller or growth-stage companies like Maze Therapeutics.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the CEO's sale as a potential negative signal, although the Rule 10b5-1 plan mitigates insider trading concerns.
• Employees: May be influenced by the CEO's stock sales in their own investment decisions regarding company stock options or grants.
• Management: The sale reflects personal financial planning by the CEO, separate from company operational performance.

Next Steps

• Continued monitoring of Maze Therapeutics' stock performance and any further insider transactions.
• Review of future SEC filings for updates on the company's financial health and strategic direction.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Maze Therapeutics, MAZE, CEO, Stock Sale, Beneficial Ownership, SEC Filing